AOTI, Inc. AI Stock Analysis
Want to see GB:AOTI full AI Analyst Report?
AOTI, Inc. (AOTI) AI Stock Analysis
AOTI, Inc.
(LSE:AOTI)
AOTI's overall score is primarily driven by strong technical momentum and a highly optimistic earnings call, highlighted by a proposed CMS coverage milestone that could exponentially expand its addressable market. The stock is in a robust uptrend across all major moving averages. However, the score is tempered by a high valuation premium and mixed financial fundamentals; despite achieving GAAP profitability, historical structural cash burn, rising leverage, and uncollected Arizona Medicaid receivables present notable risks.
AOTI, Inc. (AOTI) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 154.22M
- Dividend Yield
- ―
- Average Volume (3M)
- 149.34K
- Price to Earnings (P/E)
- 76.2
- Beta (1Y)
- 0.18
- Revenue Growth
- 10.59%
- EPS Growth
- ―
- Country
- UK
- Employees
- 90
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
AOTI, Inc. Business Overview & Revenue Model
Company Description
AOTI, Inc. specializes in creating and marketing healthcare technologies specifically designed for treating persistent and hard-to-heal wounds. Among its offerings are the innovative Topical Wound Oxygen (TWO2) Therapy and the NEXA Negative Pressure...
How the Company Makes Money
AOTI makes money primarily by selling and/or renting its topical oxygen therapy systems and the associated single-use or recurring-use consumables required to operate those systems (e.g., wound dressings and related supplies used with the therapy). R...
AOTI, Inc. Earnings Call Summary
The call was strongly optimistic, emphasizing 18.8% underlying growth, improved EBITDA margins, positive operating cash flow, clinical evidence, and the potential for CMS coverage to expand the addressable market by 65-fold. The main challenges were unpaid Arizona Medicaid receivables, slower Medicaid expansion, ongoing operational changes, and uncertainty over final Medicare reimbursement. Positive developments and stated opportunities significantly outweighed the disclosed challenges.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For the rest of 2026, AOTI is expecting 2026 EBITDA to be in line with current consensus, which is $6.8 million as at 29th of September, and is confident with its net debt and cash outlook for the full year; it is expecting to continue its top-line growth in line with its guidance set at the time of its FY 2025 results, namely underlying mid-teens growth excluding Arizona Medicaid or low single-digit growth on a reported basis. The company expects to move towards the final LCD within the 365-day period, with the final LCD to complete by July 23rd of next year, and believes average patients per rep, currently around 20, could potentially double in the future, while its highest performing reps produce as much as five times as many as that.
AOTI, Inc. Financial Statement Overview
Summary
AOTI demonstrates strong top-line growth and a return to GAAP profitability. However, sharp gross margin contraction, increasing debt levels, and persistent negative cash flows highlight near-term liquidity and leverage risks.
Income Statement
75PositiveBalance Sheet
60NeutralCash Flow
35Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 67.77M | 68.80M | 58.36M | 43.92M | 33.51M | 22.98M |
| Gross Profit | 36.40M | 37.01M | 51.35M | 37.59M | 2.86M | 45.36K |
| EBITDA | 7.79M | 7.95M | 2.64M | -4.28M | 3.19M | 16.52K |
| Net Income | 2.64M | 2.76M | -1.76M | -8.19M | -2.80M | 2.03M |
Balance Sheet | ||||||
| Total Assets | 57.01M | 57.01M | 39.54M | 21.08M | 9.35M | 1.51M |
| Cash, Cash Equivalents and Short-Term Investments | 13.44M | 13.44M | 9.34M | 778.48K | 2.83M | 297.44K |
| Total Debt | 21.19M | 21.19M | 8.92M | 12.35M | 12.41M | 269.08K |
| Total Liabilities | 37.06M | 37.06M | 22.10M | 26.99M | 5.94M | 1.25M |
| Stockholders Equity | 19.94M | 19.94M | 17.44M | -5.91M | 760.20K | 1.52M |
Cash Flow | ||||||
| Free Cash Flow | -6.74M | -6.83M | -7.85M | -2.76M | 1.77M | -428.43K |
| Operating Cash Flow | -4.91M | -4.96M | -5.91M | -1.45M | 2.77M | -46.07K |
| Investing Cash Flow | -1.83M | -1.87M | -1.94M | -1.59M | -3.13M | -904.53K |
| Financing Cash Flow | 10.99M | 11.07M | 16.41M | -202.81K | 5.72M | -692.04K |
AOTI, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AOTI, the sentiment is Positive. The current price of 145.00 is above the 20-day moving average (MA) of 136.70, above the 50-day MA of 132.98, and above the 200-day MA of 82.22, indicating a bullish trend. The MACD of 3.66 indicates Negative momentum. The RSI at 90.68 is Negative, neither overbought nor oversold. The STOCH value of 75.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AOTI.
AOTI, Inc. Peers Comparison
Overall Rating
GB:AOTI70Outperform
GB:EKF64Neutral
GB:DXRX56Neutral
GB:ABDX46Neutral
GB:RENX44Neutral
GB:VRCI41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | GBP 154.22M | 76.17 | 12.91% | ― | 10.59% | ― | |
| 64Neutral | GBP 102.28M | 41.38 | 3.58% | ― | 2.26% | -57.04% | |
| 56Neutral | GBP 161.28M | -573.44 | -0.68% | ― | 20.14% | 82.22% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | GBP 21.48M | -15.45 | -34.31% | ― | 30.42% | 43.16% | |
| 44Neutral | GBP 35.87M | -3.21 | 675.00% | ― | ― | ― | |
| 41Neutral | GBP 12.33M | -0.45 | -127.57% | ― | 77.87% | 84.36% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:AOTI | AOTI, Inc. | 145.00 | 107.50 | 286.67% | |
| GB:EKF | EKF Diagnostics Holdings | 24.00 | -0.60 | -2.44% | |
| GB:RENX | Renalytix Plc OTC | 5.20 | -1.55 | -22.96% | |
| GB:DXRX | Diaceutics Plc | 183.50 | 21.00 | 12.92% | |
| GB:VRCI | Verici Dx Plc | 0.17 | -0.52 | -75.00% | |
| GB:ABDX | Abingdon Health PLC | 8.50 | 1.25 | 17.24% |
AOTI, Inc. Corporate Events
AOTI builds momentum ahead of transformative Medicare decision as H1 revenue and EBITDA climb
PositiveAOTI reported robust underlying performance for the first half of 2026, with revenue growth of 18.8 percent excluding Arizona Medicaid and EBITDA rising 16.6 percent to 3.6 million dollars, while operating cash flow turned positive and net debt edged...
AOTI Gains Unanimous Support in CMS Meeting on Medicare Coverage for Topical Oxygen Therapy
PositiveAOTI, Inc., a medical technology group specializing in topical oxygen therapy for chronic wounds and diabetic foot ulcers, delivers its patented TWO2 therapy as a non-invasive, home-based treatment designed to improve clinical outcomes and lower heal...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 01, 2026
